31. Brechot C, et al. Impact of HBV, HCV, and GBV C/HGV on hepatocellular carcinomas in Europe: results of a European concerted
action. J Hepatol. 1998;29:173–83.
32. Buendia MA, Paterlini P, Tiollais P, Brechot C. Hepatocellular carcinoma: molecular aspects. Zuckerman AJ, Thomas CT,
editors. In: Viral Hepatitis. Livingstone, London: Churchill;1998, pp. 179–200.
33. Kang HA, Gellissen G. Hansenula polymorpha. Gellissen G, editor. In: Production of recombinant proteins. Weinheim, Germany: Wiley VCH;2005, pp. 319–359.
34. Rutgers T, et al. Expression of different forms of hepatitis B virus envelope proteins in yeast. Zuckerman A, editor.
In: Viral Hepatitis and Liver Disease. New York: A. R. Liss;1988, pp. 304–308.
35. Dupont J, et al. A controlled clinical trial comparing nthe safety and immunogenicity of new adjunvanted hepatitis B vaccine
with a standard hepatitis B vaccine. Vaccine. 2006;24:7167–74.
36. Cooper CL, et al. CPG7909 improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.
AIDS. 2005;19:1473–79.
37. Lobaina Y, Palenzuela D, Pichardo D, Muzio V, Guillén G, Aguilar JC. Immunological charcaterization of two hepatitis B
core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen. Mol Immunol. 2005;42;289–294.
38. Zhang Q, Xue X, Qu L, Pan W. Construction and evaluation of a multistage combination vaccine against malaria. Vaccine.
2007;25:2112–9.
39. Webb RP, Smith TJ, Wright PM, Montgomery VA, Meagher MM, Smith LA. Protection with recombinant Clostridium botulinum C1
and D binding domain subunit (Hc) vaccines against C and D neurotoxins. Vaccine. 2007:25:4273–82.
|
